珠海润都制药股份有限公司 战略委员会工作细则 珠海润都制药股份有限公司 战略委员会工作细则 第一章 总 则 第一条 为适应公司战略发展需要，增强公司核心竞争力，确定公司发展规 划，健全投资决策程序，加强决策科学性，提高重大投资决策的效益和决策的质 量，完善公司治理结构，根据《中华人民共和国公司法》（以下简称《公司法》）、 《上市公司治理准则》《珠海润都制药股份有限公司章程》（以下简称《公司章 程》）及其他有关法律、法规、规范性文件的规定，公司特设立董事会战略委员 会，并制定本工作细则。 第二条 董事会战略委员会是董事会按照股东大会决议设立的专门工作机 构，主要负责对公司长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 战略委员会由 5 名董事组成，其中 1 名为独立董事。 第四条 战略委员会委员由董事长、1/2 以上独立董事或者全体董事的 1/3 提 名，并由董事会选举产生。 1 珠海润都制药股份有限公司 战略委员会工作细则 （三）对《公司章程》规定须经董事会批准的重大资本运作、资产经营项目 进行研究并提出建议； 第五条 战略委员会设主任委员（召集人）1 名，由公司董事长担任。 第六条 ...

珠海润都制药股份有限公司 提名委员会工作细则 珠海润都制药股份有限公司 提名委员会工作细则 第一章 总 则 第一条 为规范和完善珠海润都制药股份有限公司（以下简称"公司"）董事、 总经理及其他高级管理人员的产生，优化董事会及经营管理层的组成，完善公司治理 结构，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司治 理准则》、《深圳证券交易所股票上市规则》、《珠海润都制药股份有限公司章程》 （以下简称"《公司章程》"）及其他有关法律、法规、规范性文件的规定，公司特 设立董事会提名委员会，并制定本细则。 第二条 董事会提名委员会是董事会按照股东大会决议设立的专门工作机构，主 要负责对公司董事和总经理等高级管理人员的人选、选择标准和程序进行选择并提出 建议。 第二章 人员组成 第三条 提名委员会成员由3名董事组成，独立董事应占半数以上。 第四条 提名委员会委员由董事长、1/2以上独立董事或者全体董事的1/3提名， 并由董事会选举产生。 第五条 提名委员会设主任委员（召集人）1名，由独立董事委员担任，负责主持 提名委员会工作。主任委员由董事会选举产生。 第六条 提名委员会任期与董事会任期一致，委员任期 ...

珠海润都制药股份有限公司 薪酬与考核委员会工作细则 珠海润都制药股份有限公司 薪酬与考核委员会工作细则 第一章 总 则 第一条 为健全公司董事（非独立董事，下同）及高级管理人员（以下简称"高管"） 的考核与薪酬管理制度，完善公司治理结构，规范工作程序，根据《中华人民共和国 公司法》（以下简称《公司法》）、《上市公司治理准则》《深圳证券交易所股票上市规则》 （以下简称《股票上市规则》）、以及《珠海润都制药股份有限公司章程》（以下简称 《公司章程》）及其他有关法律、法规、规范性文件的规定，公司特设立董事会薪酬与 考核委员会，并制定本工作细则。 第二条 董事会薪酬与考核委员会是董事会按照股东大会决议设立的专门工作机 构，直接对董事会负责，主要负责制定公司董事及高级管理人员（以下简称"高管"） 的考核标准并进行考核，负责制定、审查公司董事及高管的薪酬政策与方案。 第三条 本细则所称董事是指在本公司领取薪酬的董事，高管是指董事会聘任的总 经理、副总经理、董事会秘书、财务负责人及经董事会聘任的其他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由公司 3 名董事组成，其中独立董事占 1/2 以上。 第五条 ...

证券代码：002923 证券简称：润都股份 公告编号：2023-044 珠海润都制药股份有限公司 关于公司控股股东及共同实际控制人 部分股份解除质押及质押续期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 1、证券质押及司法冻结明细表。 2、股票质押式回购交易延期购回补充协议。 3、股票质押式回购交易部分解除质押补充协议。 注：鉴于公司于2023年5月31日实施了2022年度权益分派方案。权益分派方案为：以公司现 有239,209,490股为基数，向全体股东每10股派3.500000元人民币现金，共计分配现金红利 人民币83,723,321.50元（含税），以资本公积金向全体股东每10股转增4.000000股；转增 后公司总股本由239,209,490股增加至334,893,286股；李希先生持有公司股份由72,047,137 股增加至100,865,992股；2022年8月9日在华西证券质押及补充质押的股份由17,000,700 股 增加至23,800,980股。本次解除质押的股份为2,603,980股，质押续期的股份为21,197,000 股，质押 ...

证券代码： 002923 证券简称：润都股份 珠海润都制药股份有限公司投资者关系活动记录表 编号：2023-001 | 投资者关系活 | 分析师会议 □特定对象调研 □ | | --- | --- | | 动类别 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | 其他 （请文字说明其他活动内容） □ | | 参与单位名称 | 投资者网上提问 | | 及人员姓名 | | | 时间 | 年 月 日 (周三) 下午 2023 5 17 15:00~17:00 | | 地点 | 公司通过中证路演中心（https://www.cs.com.cn/roadshow/）采 | | | 用网络远程的方式召开业绩说明会 | | 上市公司接待 | 1、润都股份 董事长陈新民 | | 人员姓名 | 2、润都股份 董事、总经理刘杰 | | | 3、润都股份 独立董事叶建木 | | | 4、润都股份 财务负责人、副总经理石深华 | | | 5、润都股份 董事会秘书苏军 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | ...

证券代码：002923 证券简称：润都股份 公告编号：2023-033 珠海润都制药股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 珠海润都制药股份有限公司（以下简称"公司"）已于2023年04月27日在巨潮 资讯网（http://www.cninfo.com.cn）披露了《2022年度报告》及《2022年度报 告摘要》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情 况，公司定于2023年05月17日（星期三）15:00-17:00在中证路演中心举办2022 年度网上业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2023年05月17日（星期三）15:00-17:00 会议召开地点：中证路演中心（https://www.cs.com.cn/roadshow/） 会议召开方式：网络互动方式 二、公司出席人员 董事长陈新民先生、董事兼总经理刘杰先生、独立董事叶建木先生、副总经 理兼财务负责人石深华先生、董事会秘书苏军先生。 四、 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 359,359,020.73, representing an increase of 11.35% compared to CNY 322,719,191.72 in the same period last year[5]. - The net profit attributable to shareholders was CNY 40,432,140.73, up by 6.05% from CNY 38,124,057.71 year-on-year[5]. - Basic and diluted earnings per share were both CNY 0.17, reflecting a 6.25% increase from CNY 0.16 in the previous year[5]. - Total operating revenue for Q1 2023 was CNY 359,359,020.73, an increase of 11.3% compared to CNY 322,719,191.72 in Q1 2022[17]. - Net profit for Q1 2023 reached CNY 40,432,140.73, representing a 6.1% increase from CNY 38,124,057.71 in Q1 2022[18]. - Earnings per share for Q1 2023 were CNY 0.17, compared to CNY 0.16 in Q1 2022, indicating a growth of 6.25%[18]. Cash Flow and Operating Activities - The cash flow from operating activities showed a net outflow of CNY 38,129,239.46, a decrease of 107.03% compared to the previous year's outflow of CNY 18,417,173.83[5]. - The cash inflow from operating activities for Q1 2023 was approximately CNY 289.51 million, an increase from CNY 268.75 million in Q1 2022, representing a growth of about 7.5%[21]. - The net cash outflow from operating activities was CNY -38.13 million, worsening from CNY -18.42 million in the same period last year[21]. - The company’s cash flow from operating activities was negatively impacted by increased payments to employees, which rose to CNY 81.79 million from CNY 66.81 million, an increase of approximately 22.4%[21]. - The cash paid for purchasing goods and services was CNY 75.99 million, a decrease from CNY 111.26 million in the same quarter last year, indicating a reduction of about 31.7%[21]. - The company reported a decrease in cash received from other operating activities, totaling CNY 2.23 million, down from CNY 4.24 million in Q1 2022[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,260,733,963.54, a decrease of 1.12% from CNY 2,286,349,976.81 at the end of the previous year[5]. - Total current assets decreased from CNY 946,245,552.06 at the beginning of the year to CNY 916,719,433.96 by the end of the quarter, a decline of approximately 3.4%[13]. - Total liabilities decreased to CNY 1,024,317,604.57 from CNY 1,090,365,758.57 year-over-year, a reduction of approximately 6.1%[15]. - Cash and cash equivalents decreased from CNY 221,031,587.61 to CNY 195,499,183.52, representing a decrease of about 11.5%[13]. - Inventory decreased slightly from CNY 440,855,177.61 to CNY 435,694,370.35, a reduction of approximately 1.0%[13]. - Non-current assets increased marginally from CNY 1,340,104,424.75 to CNY 1,344,014,529.58, an increase of about 0.3%[13]. - Fixed assets decreased from CNY 925,441,043.51 to CNY 919,305,937.56, a decline of approximately 0.7%[13]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,596[10]. - The top two shareholders, Li Xi and Chen Xinmin, each hold 30.12% of the shares, totaling 72,047,137 shares each[10]. - The total number of shares held by the top 10 shareholders accounted for 60.24% of the total share capital at the end of the reporting period[10]. Tax and Expenses - The income tax expense rose by 117.12% to CNY 7,867,857.79, attributed to an increase in corporate income tax expenses[8]. - The company experienced a 72.86% increase in tax payments, totaling CNY 48,187,207.40, compared to CNY 27,876,178.81 in the previous year[8]. - Research and development expenses for Q1 2023 were CNY 20,054,037.85, slightly down from CNY 21,615,040.10 in Q1 2022, indicating a decrease of 7.2%[17]. Other Information - The company reported a significant decrease in contract liabilities by 79.76%, from CNY 46,683,747.70 to CNY 9,449,100.15, due to a reduction in advance payments[8]. - The company recorded a 169.49% increase in non-operating income, amounting to CNY 802,136.79, primarily due to the disposal of long-term contract liabilities[8]. - The company has not disclosed any new product developments or market expansion strategies in the current report[12]. - The company has not disclosed specific future outlook or guidance in the provided documents[19]. - There are no mentions of new products, technologies, market expansions, or mergers in the provided content[19].

Dividend Distribution - The company plans to distribute a cash dividend of 3.5 yuan per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company plans to distribute cash dividends of 3.50 yuan per 10 shares, totaling 83,723,321.50 yuan, which represents 100% of the profit distribution[172]. - The total distributable profit for the parent company is 653,300,554.21 yuan, after accounting for a legal surplus reserve of 22,777,352.40 yuan[173]. Financial Performance - The company's operating revenue for 2022 was ¥1,372,233,917, representing a 15.32% increase compared to ¥1,189,926,867 in 2021[21]. - Net profit attributable to shareholders for 2022 was ¥155,476,936.73, an increase of 11.24% from ¥139,766,332.61 in 2021[21]. - The net profit after deducting non-recurring gains and losses was ¥138,572,724.87, up 9.43% from ¥126,633,376.77 in 2021[21]. - Basic earnings per share for 2022 were ¥0.65, a 12.07% increase from ¥0.58 in 2021[21]. - Total assets at the end of 2022 were ¥2,286,349,976, reflecting a 19.74% increase from ¥1,909,438,088 at the end of 2021[21]. - Net assets attributable to shareholders increased by 7.54% to ¥1,195,984,218 from ¥1,112,155,581 in 2021[21]. - The company reported a quarterly revenue of ¥380,255,079.02 in Q4 2022, with a net profit of ¥53,853,661.06 for the same quarter[25]. - The company's formulation revenue reached 860.814 million yuan in 2022, representing a year-on-year growth of 12.28%, accounting for 62.73% of total revenue[60]. - The raw material drug manufacturing segment generated ¥502,408,912.32, which is 36.61% of total revenue, showing a year-on-year increase of 19.25%[82]. - The total cost of goods sold for 2022 was ¥600,789,626, marking a 30.94% increase from ¥458,836,067 in 2021, primarily due to expanded sales scale[87]. Risk Management - The company has outlined various risks and countermeasures in its annual report, ensuring transparency for investors[4]. - The company has confirmed that there are no significant risks affecting its production and operations during the reporting period[4]. - The company has established a comprehensive risk management framework to address potential operational challenges[4]. - The company has maintained a consistent attendance record at board meetings, with no directors missing two consecutive meetings[156]. - The company did not face any significant risks during the reporting period, as confirmed by the supervisory board[162]. Research and Development - The company is committed to enhancing its R&D capabilities by recruiting specialized talent and increasing investment in research and development[47]. - The company invested approximately 95.59 million yuan in R&D in 2022, accounting for 6.97% of its revenue, continuing a trend of significant investment in innovation[64]. - The company has a research team of over 200 personnel, with more than 80% holding bachelor's degrees or higher, and approximately 11.81% holding doctoral or master's degrees[63]. - The company is actively involved in the development of new drugs and technologies to meet market demands and improve patient outcomes[140]. - The company has established a wholly-owned R&D subsidiary in Wuhan, enhancing its research capabilities and infrastructure[69]. Market Position and Strategy - The pharmaceutical manufacturing industry is a strategic sector crucial for national health and economic development, with significant growth achieved since the 13th Five-Year Plan[32]. - The company has achieved vertical integration in the production of antihypertensive drugs, leading in domestic market supply of certain raw materials[38]. - The company is expanding its international market presence, with products sold in Europe, the USA, Japan, South Korea, and actively exploring markets in the Middle East, South Asia, Southeast Asia, and South America[50]. - The company aims to improve the clinical specialty capabilities of county-level hospitals, which is expected to increase the usage of specialized drugs and medical consumables[46]. - The company plans to launch three new products in the next quarter, focusing on innovative drug formulations[146]. Governance and Management - The company has a robust governance structure in place, with all board members present for the report's approval[4]. - The company has established a clear governance structure with independent directors and management, ensuring effective oversight and decision-making[134]. - The company has a strong leadership team with Chen Xinmin serving as Chairman since October 2018, bringing extensive experience in the pharmaceutical industry[138]. - The company has independent directors who received CNY 9.47 million each during the reporting period[154]. - The company has a total of 12 directors and supervisors, with varying remuneration levels based on their roles and responsibilities[153]. Compliance and Internal Control - The company is committed to maintaining compliance with regulatory standards and has detailed its adherence to relevant accounting principles[13]. - The company maintains a robust internal control system, with no significant defects identified in financial and non-financial reporting controls for 2022[186]. - The internal control self-assessment report indicates that 100% of the total assets and operating income of the evaluated units are included in the consolidated financial statements[189]. - The company recognizes the importance of compliance with laws and regulations to avoid penalties and operational disruptions[190]. - The company has established a comprehensive governance framework and effectively executed it, with no identified need for rectification during the self-inspection process[192]. Employee and Training - The total number of employees at the end of the reporting period is 1,891, with 1,202 in the parent company and 154 in major subsidiaries[163]. - The company has established a comprehensive training program, focusing on both professional and managerial talent development, with various training initiatives conducted[168]. - The employee composition includes 1,015 production personnel, 215 sales personnel, 527 technical personnel, 30 financial personnel, and 104 administrative personnel[163]. - The total number of employees with a master's degree or above is 48, while those with a bachelor's degree are 509, and those with a diploma or below are 1,343[163]. Environmental Compliance - The company strictly adheres to environmental protection policies, with wastewater and air emissions meeting regulatory standards[196]. - The wastewater discharge limits were relaxed by 200% after obtaining a new discharge permit in May 2022[196]. - The company’s noise emissions comply with the Class 3 standards of the Industrial Enterprise Boundary Noise Emission Standards[197]. - The company has implemented online monitoring devices at major discharge points, connected to environmental authorities[198]. - Hazardous waste management follows national regulations, ensuring proper storage, transfer, and disposal[200].

珠海润都制药股份有限公司 投资者关系活动记录表 证券简称：润都股份 证券代码：002923 编号：2019-002 | --- | --- | --- | |--------------|-------------------------|------------------------------------------------------------| | | | | | | □ | 特定对象调研 □ 分析师会议 | | | □ | 媒体采访 □ 业绩说明会 | | 投资者关系活 | □ | 新闻发布会 □ 路演活动 | | 动类别 | □ 现场参观 | | | | √ 其他（ 2019 | 广东辖区上市公司投资者关系管理月活动投资者 | | | 集体接待日） | | | 参与单位名称 | 参与公司 2019 | 广东辖区上市公司投资者关系管理月活动投资 | | 及人员姓名 | | 者集体接待日的不特定投资者 | | 时间 | 2019 年 5 月 22 | 日（星期三）下午 14:00-16:45 | | 地点 | 全景•路演天下（ | http://rs.p5w.net ） | | 上市公司接待 ...

珠海润都制药股份有限公司 投资者关系活动记录表 证券简称：润都股份 证券代码：002923 编号：2019-001 | --- | --- | --- | |-------------------------|------------------------|------------------------------------------------------| | | | | | | □ | 特定对象调研 □ 分析师会议 | | | □ 媒体采访 | √ 业绩说明会 | | 投资者关系活 动类别 | □ | 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 参与公司 2018 | 年年度报告网上说明会的不特定投资者 | | 时间 | 2019 年 5 月 6 | 日（星期一）下午 15:00-17:00 | | | | | | 地点 | 全景•路演天下（ | http://rs.p5w.net ） | | | 总经理：刘杰先生 | | | 上市公司接待 | | 副总经理/董事会秘书：曾勇先生 | | 人员姓 ...